SlateStone Wealth LLC Buys New Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

SlateStone Wealth LLC bought a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,200 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Other hedge funds have also modified their holdings of the company. Capital Investment Counsel Inc grew its position in Bristol-Myers Squibb by 3.4% in the fourth quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 200 shares in the last quarter. James Investment Research Inc. grew its position in Bristol-Myers Squibb by 36.5% in the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 219 shares in the last quarter. Squar Milner Financial Services LLC grew its position in Bristol-Myers Squibb by 5.6% in the first quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 223 shares in the last quarter. Seizert Capital Partners LLC grew its position in Bristol-Myers Squibb by 3.8% in the fourth quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 224 shares in the last quarter. Finally, Modera Wealth Management LLC grew its position in Bristol-Myers Squibb by 4.3% in the fourth quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 229 shares in the last quarter. 77.65% of the stock is currently owned by institutional investors and hedge funds.

BMY has been the subject of several research reports. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $51.00 target price for the company in a research report on Tuesday, April 23rd. BMO Capital Markets reiterated a “buy” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Goldman Sachs Group initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price for the company. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Finally, Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price for the company. in a research report on Monday, May 20th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $56.34.

NYSE BMY opened at $47.33 on Friday. The company has a quick ratio of 1.79, a current ratio of 1.93 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 12-month low of $44.30 and a 12-month high of $63.69. The stock has a market cap of $77.91 billion, a price-to-earnings ratio of 11.89, a price-to-earnings-growth ratio of 2.23 and a beta of 0.74.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The business had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the business posted $0.94 earnings per share. The company’s revenue was up 14.0% on a year-over-year basis. Sell-side analysts predict that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current fiscal year.

In other news, insider Karen Murphy Santiago sold 3,065 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the transaction, the insider now directly owns 3,066 shares of the company’s stock, valued at $145,818.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II acquired 5,000 shares of the stock in a transaction dated Thursday, May 16th. The shares were purchased at an average cost of $47.29 per share, with a total value of $236,450.00. Following the completion of the purchase, the director now owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Corporate insiders own 0.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “SlateStone Wealth LLC Buys New Holdings in Bristol-Myers Squibb Co (NYSE:BMY)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2019/06/14/slatestone-wealth-llc-buys-new-holdings-in-bristol-myers-squibb-co-nysebmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.